AlphaCentric Advisors’s AbbVie ABBV Stock Holding History

AlphaCentric Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$909K	Buy	3,613 +69	+2%	+$14.8K	0.77%	31
2026 Q1	$771K	Buy	3,544 +565	+19%	+$125K	0.77%	32
2025 Q4	$681K	Buy	+2,979	New	+$679K	0.68%	40
2024 Q4	$2.31M	Buy	+13,018	New	+$2.39M	2.31%	5
2023 Q2	–	Sell	-1,679	Closed	-$268K	–	233
2023 Q1	$268K	Sell	1,679 -14	-0.8%	-$2.14K	0.18%	116
2022 Q4	$274K	Buy	1,693 +358	+27%	+$54.9K	0.27%	109
2022 Q3	$179K	Buy	+1,335	New	+$192K	0.18%	123
2021 Q3	–	Sell	-425	Closed	-$48K	–	195
2021 Q2	$48K	Hold	425	–	–	0.01%	201
2021 Q1	$46K	Hold	425	–	–	0.02%	193
2020 Q4	$46K	Hold	425	–	–	0.02%	185
2020 Q3	$37K	Hold	425	–	–	0.02%	124
2020 Q2	$42K	Buy	+425	New	+$37.4K	0.02%	92

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AlphaCentric Advisors's ABBV Position: Q2 2026 in Review

AlphaCentric Advisors increased its AbbVie (ABBV) stake by 1.9% in Q2 2026, buying an estimated $14.8K and bringing the position to 3,613 shares worth $909K. The position accounts for 0.77% of the portfolio, ranked #31.

AlphaCentric Advisors first reported a position in ABBV in Q2 2020 and has held it in 12 quarters since. The position peaked at $2.31M in Q4 2024. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

AlphaCentric Advisors held 3,613 shares of AbbVie worth $909K as of Q2 2026.
AlphaCentric Advisors bought 69 AbbVie shares in Q2 2026, an estimated $14.8K.
AbbVie made up 0.77% of AlphaCentric Advisors's portfolio in Q2 2026, its #31 holding.
AlphaCentric Advisors first reported a position in AbbVie in Q2 2020 and has held it in 12 quarters since.
AlphaCentric Advisors's AbbVie position peaked at $2.31M in Q4 2024.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.